Makoto Akiyama^*†, Yoshihiro Sowa^*, Tomoyuki Taniguchi^*, Motoki Watanabe^*, Shingo Yogosawa^‡, Jo Kitawaki^†,Toshiyuki Sakai^*

Oncology Research, Vol.25, No.8, pp. 1245-1252, 2017, DOI:10.3727/096504017X14850164661097

Abstract Ovarian cancer is the most lethal disease among gynecological malignancies. More effective therapy is required to counter high recurrence rates and chemotherapy resistance. We investigated the efficacy and molecular mechanisms of three combined treatments (TCTs)—a novel histone deacetylase (HDAC) inhibitor OBP-801/YM753, 5-fluorouracil (5-FU), and paclitaxel (PTX)—in human ovarian cancer SKOV-3 and OVCAR-3 cells. The inhibition of cell growth was stronger with TCTs than with each single agent and with two combined treatments. The TCTs significantly induce G₂ phase arrest in both cell lines. We then analyzed the molecular mechanisms and found that the TCTs increased the More >

Akinobu Furutani^*†, Yoshihiro Sowa^*, Hitoshi Fujiwara^†, Eigo Otsuji^†, Toshiyuki Sakai^*

Oncology Research, Vol.23, No.1-2, pp. 87-87, 2015, DOI:10.3727/096504016X14514194509664

Abstract Histone deacetylase (HDAC) inhibitors have been shown to enhance the effects of 5-fluorouracil (5-FU) against various cancer cells; however, no report has shown that an HDAC inhibitor may enhance the effects of 5-FU with radiation. Therefore, we investigated whether the novel HDAC inhibitor OBP-801/YM753 could enhance the effects of 5-FU with radiation on esophageal squamous carcinoma KYSE170 cells. The inhibition of the cell growth was significantly stronger with the combination of OBP-801/YM753 with 5-FU than with the 5-FU treatment only. Furthermore, inhibition of the colony formation was the most effective with the combined treatment of More >